You are viewing: France Theranostics Market analysis
Part of: Theranostics Market (Global)

The France Theranostics Market was valued at $86.4 Million in 2023 and projected to reach to $163.8 Million by 2028, representing a compound annual growth rate of 13.6%. France's theranostics market is poised for significant expansion through 2028, driven by increasing adoption of precision medicine approaches and substantial investments in advanced healthcare infrastructure.

France Theranostics Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Theranostics Market Trends and Insights

  • This growth trajectory reflects France's strengthening position in precision medicine and diagnostic-therapeutic integration within the European healthcare landscape.
  • France's investment in advanced healthcare infrastructure and regulatory support for innovative diagnostic solutions are driving adoption of theranostic approaches across oncology, cardiology, and neurology applications. The French theranostics market benefits from robust pharmaceutical research capabilities and a well-established healthcare reimbursement system that increasingly recognizes the value of combined diagnostic-therapeutic solutions.
  • Between 2023 and 2028, France is expected to see accelerated clinical adoption driven by rising demand for personalized treatment strategies and improved patient outcomes.
  • France's participation in European regulatory frameworks and collaborative research initiatives further positions the country as a key growth market for theranostic technologies in the region..

Key Market Statistics

  • CAGR (2023-2028) 13.6% CAGR
  • Market Size, 2023 ~USD 86.4 Million
  • Forecast, 2028 ~USD 163.8 Million
  • Country France

France Theranostics Market Overview

Market Valuation Growth :

France's theranostics market reached $86.4 million in 2023 and is expected to nearly double to $163.8 million by 2028, demonstrating strong market expansion driven by precision medicine adoption.

Robust CAGR Performance :

With a 13.6% CAGR from 2023-2028, France's theranostics market outpaces many European counterparts, reflecting increased healthcare investment and regulatory support for integrated diagnostic-therapeutic solutions.

Precision Medicine Leadership :

France is strengthening its position as a European hub for precision medicine, with healthcare infrastructure investments supporting the integration of diagnostics and therapeutics in clinical practice.

European Healthcare Integration :

France's theranostics advancement aligns with broader European healthcare modernization, positioning the country as a key market for companies seeking to expand precision medicine capabilities across the continent.

France Theranostics Market Dynamics

  • The country's regulatory environment and healthcare system are increasingly supportive of integrated diagnostic-therapeutic solutions, creating favorable conditions for market growth.
  • French healthcare providers are progressively integrating theranostic approaches into clinical workflows, particularly in oncology and cardiovascular disease management. The 13.6% CAGR reflects growing demand from hospitals, diagnostic centers, and pharmaceutical companies seeking to develop and deploy theranostic solutions.
  • France's position within the European Union provides additional advantages for market players, including access to broader European markets and participation in collaborative research initiatives.
  • Continued government support for healthcare innovation and precision medicine will likely sustain this growth trajectory through the forecast period..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • Merck KGaA
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • France's theranostics market is valued at $86.4 million in 2023 and will nearly double to $163.8 million by 2028.
    • France demonstrates a 13.6% CAGR, reflecting strong adoption of precision medicine and integrated diagnostic-therapeutic solutions.
    • France's advanced healthcare infrastructure and reimbursement policies support accelerated clinical implementation of theranostic technologies.
    • France is positioned as a key European growth market driven by personalized treatment demand and regulatory support for innovation.

    Theranostics Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment THERANOSTICS CENTERS (End User)
    Forecast Period 2023-2028
    Growth Rate CAGR of 15.5% from 2023 to 2028
    Largest Segment RADIOPHARMACEUTICALS (Product)
    Market Size Base Year (Billions) ~USD 2.09 (2023)
    Revenue Forecast (Billions) ~USD 4.3 (2028)
    Segments Covered Product, Type, Application, End User

    France Theranostics Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Diagnostic Imaging
    • Ivd/Biomarker Screening
    • Radiopharmaceuticals
    • Software & Services

    By Type

    • Iodine-131
    • Lutetium-177
    • Other Radiopharmaceuticals
    • Radium-223
    • Samarium-153
    • Yttrium-90

    By Application

    • Bone Metastasis
    • Other Applications
    • Other Cancer
    • Other Cancers
    • Prostate Cancer

    By End User

    • Hospitals And Cancer Care Centers
    • Research And Academic Centers
    • Theranostics Centers

    Target Audience

    • Pharmaceutical & Biotech Companies : Need France-specific market data to guide R&D investments, clinical trial planning, and commercialization strategies for theranostic drug-diagnostic companion products targeting the French and broader European markets.
    • Medical Device Manufacturers : Require detailed market sizing and growth forecasts for France to assess market entry feasibility, competitive landscape, and revenue potential for diagnostic imaging and theranostic platform technologies.
    • Healthcare Investors & PE Firms : Seek validated market data on France's theranostics sector to evaluate investment opportunities, assess portfolio company growth potential, and identify acquisition targets within the precision medicine space.
    • Hospital & Diagnostic Center Operators : Need market intelligence on theranostic adoption trends and growth projections in France to inform capital allocation decisions, service expansion planning, and technology infrastructure investments.
    • Healthcare Consultants & Analysts : Require comprehensive France-specific theranostics market data to support client advisory work, competitive benchmarking, and strategic planning for healthcare organizations and life sciences companies.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for France's theranostics market with verified 2023 baseline ($86.4M) and 2028 forecast ($163.8M), enabling accurate business planning and investment decisions specific to this high-growth European market.
    • Competitive Positioning Strategy : Understand France's 13.6% CAGR performance relative to global trends (15.5%), identifying market gaps and competitive opportunities for theranostic solution providers entering or expanding within the French healthcare system.
    • Regulatory & Infrastructure Insights : Access detailed analysis of France's healthcare infrastructure investments and regulatory environment supporting precision medicine adoption, critical for companies developing theranostic products for European commercialization.
    • Strategic Market Entry Planning : Leverage France-specific market intelligence to develop targeted go-to-market strategies, including identification of key stakeholders, reimbursement pathways, and clinical adoption drivers within the French healthcare ecosystem.
    • Investment & Partnership Opportunities : Identify high-potential investment and partnership opportunities in France's expanding theranostics sector, supported by quantified market projections and growth drivers specific to the French precision medicine landscape.

    Frequently asked questions

    What is the current size of France's theranostics market?

    France's theranostics market was valued at $86.4 million in 2023 and is expected to reach $163.8 million by 2028.

    What is the growth rate of theranostics in France?

    France's theranostics market is growing at a compound annual growth rate (CAGR) of 13.6% from 2023 to 2028.

    What factors are driving theranostics adoption in France?

    France's growth is driven by advanced healthcare infrastructure, robust reimbursement systems, rising demand for personalized medicine, and regulatory support for innovative diagnostic-therapeutic solutions.

    Which therapeutic areas are leading theranostics growth in France?

    Oncology, cardiology, and neurology are the primary therapeutic areas driving theranostics adoption and market expansion in France.

    How does France's theranostics market compare to Europe?

    France is a key European growth market for theranostics, benefiting from strong pharmaceutical research capabilities and participation in collaborative European regulatory frameworks.

    RESEARCH METHODOLOGY

    The study involved four major activities in estimating the current size of the theranostics market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

    Secondary Research

    The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial theranostics market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as OEMs, CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the theranostics market. The primary sources from the demand side include medical CDMOs, oncologists, doctors, radiologists, technicians, and service providers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

    A breakdown of the primary respondents is provided below:

    Theranostics Market Size, and Share

    *Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note: Companies are classified into tiers based on their total revenue. As of 2021, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Estimation Methodology

    In this report, the theranostics market’s size was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the market business were determined through various insigh ts gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

    Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:

    • Generating a list of major global players operating in the theranostics market.
    • Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/category)
    • Revenue mapping of major players to cover a major share of the global market share, as of 2022
    • Extrapolating the global value of the theranostics market industry

    Theranostics Market Size, and Share

    Data Triangulation

    After arriving at the overall market size from the market size estimation process explained above, the global theranostics market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the market was validated using top-down and bottom-up approaches.

    Market Definition

    Theranostics is a term used for diagnosis and therapy. Theranostics can be broadly defined as a combination of molecularly targeted imaging and therapy, whereas imaging helps to gain information regarding presence of targeted moleculaes on cell surface and therapy progression. Radiotheranostics involves the use of radionuclide/radiopharmaceutical that delivers targeted radiation to kill the cancerous cells and imaging modality such as positron emission tomography (PET) is used to locate the cancer.  FDA approved theranostics procedures are performed for different applications such as prostate cancer, neuroendocrine tumor, etc. These procedures are mainly performed in hospitals, cancer care centers, and  theranostics centers.

    Key Stakeholders

    • Senior Management
    • End Users
    • R&D Department
    • Finance/Procurement Department

    Objectives of the Study

    • To define, describe, and forecast the size of theranostics market based on product, application, end user, and region
    • To provide detailed information regarding the major factors influencing the growth potential of the global market (drivers, restraints, opportunities, challenges, and trends)  
    • To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market.   
    • To analyze key growth opportunities in the global market for key stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of market segments and/or subsegments with respect to three major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, and the RoE), Asia Pacific (Japan, China, India, and the RoAPAC), and Rest of the World (Latin America and Middle East and Africa).
    • To profile the key players in the market and comprehensively analyze their market shares and core competencies.
    • To track and analyze the competitive developments undertaken in the global market, such as product launches; agreements; expansions; and mergers & acquisitions.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the present global theranostics market report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Geographic Analysis

    • Further breakdown of the Rest of Europe theranostics market into Italy, Spain Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among others
    • Further breakdown of the Rest of Asia Pacific theranostics market into Australia, South Korea, Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries

    Get the Full Theranostics Market Report

    Full forecast, segment splits, and company analysis for all Theranostics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status